{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Plasma&page=26",
    "query": {
      "condition": "Plasma",
      "page": 26
    },
    "page_size": 10
  },
  "pagination": {
    "page": 26,
    "page_size": 10,
    "total_count": 3601,
    "total_pages": 361,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Plasma&page=27&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Plasma&page=25&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-17T17:42:14.874Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01301963",
      "title": "Filgrastim With or Without Plerixafor in Treating Patients With Multiple Myeloma Previously Treated With Lenalidomide",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Refractory Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "plerixafor",
          "type": "DRUG"
        },
        {
          "name": "filgrastim",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Case Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "19 Years and older"
      },
      "enrollment_count": 9,
      "start_date": "2011-07",
      "completion_date": null,
      "has_results": true,
      "last_update_posted_date": "2014-08-06",
      "last_synced_at": "2026-11-17T17:42:14.874Z",
      "location_count": 2,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01301963"
    },
    {
      "nct_id": "NCT02963493",
      "title": "A Study of Melphalan Flufenamide (Melflufen) Plus Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "Melphalan flufenamide (Melflufen)",
          "type": "DRUG"
        },
        {
          "name": "Dexamethasone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Oncopeptides AB",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 157,
      "start_date": "2016-12-28",
      "completion_date": "2021-11-16",
      "has_results": true,
      "last_update_posted_date": "2022-11-22",
      "last_synced_at": "2026-11-17T17:42:14.874Z",
      "location_count": 9,
      "location_summary": "Whittier, California • Gainesville, Florida • Chicago, Illinois + 6 more",
      "locations": [
        {
          "city": "Whittier",
          "state": "California"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02963493"
    },
    {
      "nct_id": "NCT07032714",
      "title": "Mezigdomide and Talquetamab in Relapsed and Refractory Multiple Myeloma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Relapsed Refractory Multiple Myeloma (RRMM)"
      ],
      "interventions": [
        {
          "name": "Talquetamab",
          "type": "DRUG"
        },
        {
          "name": "Mezigdomide",
          "type": "DRUG"
        },
        {
          "name": "Dexamethasone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 25,
      "start_date": "2025-12-19",
      "completion_date": "2028-07-01",
      "has_results": false,
      "last_update_posted_date": "2026-04-13",
      "last_synced_at": "2026-11-17T17:42:14.874Z",
      "location_count": 3,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07032714"
    },
    {
      "nct_id": "NCT00811733",
      "title": "A Phase II Trial of Ofatumumab in Subjects With Waldenstrom's Macroglobulinemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Waldenstrom Macroglobulinaemia"
      ],
      "interventions": [
        {
          "name": "Ofatumumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 37,
      "start_date": "2009-03-01",
      "completion_date": "2014-02-01",
      "has_results": true,
      "last_update_posted_date": "2017-05-30",
      "last_synced_at": "2026-11-17T17:42:14.874Z",
      "location_count": 7,
      "location_summary": "Los Angeles, California • Stanford, California • Rochester, Minnesota + 4 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "Buffalo",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00811733"
    },
    {
      "nct_id": "NCT06810726",
      "title": "Evaluate Use of Tropocells(R) Autologous Platelet-rich Fibrin (PRF) for Wagner Grade 1 and Grade 2, Mild to Mod Neuroischemic Plantar Diabetic Foot Ulcer Wound Care.",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diabetic Foot Ulcer",
        "Type 1 Diabetes Mellitus",
        "Type 2 Diabetes Mellitus (T2DM)",
        "Neuroischemic Foot Ulcer",
        "Chronic Wound of the Lower Limb (Leg Ulcer or Foot Ulcer)",
        "Chronic Wound Care"
      ],
      "interventions": [
        {
          "name": "Platelet Rich Plasma",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Estar Medical dba Medical Technologies, LTD",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 30,
      "start_date": "2025-04-15",
      "completion_date": "2026-08-15",
      "has_results": false,
      "last_update_posted_date": "2025-06-12",
      "last_synced_at": "2026-11-17T17:42:14.874Z",
      "location_count": 2,
      "location_summary": "Corpus Christi, Texas",
      "locations": [
        {
          "city": "Corpus Christi",
          "state": "Texas"
        },
        {
          "city": "Corpus Christi",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06810726"
    },
    {
      "nct_id": "NCT04413357",
      "title": "Glycemic Response in Persons with Type 2 Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "Balanced Nutritional Drink",
          "type": "OTHER"
        },
        {
          "name": "Diabetes Specific, Balanced Nutritional Drink (DMA)",
          "type": "OTHER"
        },
        {
          "name": "Diabetes Specific, Balanced Nutritional Drink DMB",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Société des Produits Nestlé (SPN)",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "20 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "20 Years to 75 Years"
      },
      "enrollment_count": 14,
      "start_date": "2020-05-18",
      "completion_date": "2020-08-11",
      "has_results": false,
      "last_update_posted_date": "2024-10-21",
      "last_synced_at": "2026-11-17T17:42:14.874Z",
      "location_count": 1,
      "location_summary": "Tustin, California",
      "locations": [
        {
          "city": "Tustin",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04413357"
    },
    {
      "nct_id": "NCT02215967",
      "title": "Study of T Cells Targeting B-Cell Maturation Antigen for Previously Treated Multiple Myeloma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Myeloma, Plasma-Cell",
        "Myeloma-Multiple"
      ],
      "interventions": [
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Anti-B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T cells",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "73 Years",
        "sex": "ALL",
        "summary": "18 Years to 73 Years"
      },
      "enrollment_count": 30,
      "start_date": "2014-08-12",
      "completion_date": "2019-08-15",
      "has_results": true,
      "last_update_posted_date": "2019-10-08",
      "last_synced_at": "2026-11-17T17:42:14.874Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02215967"
    },
    {
      "nct_id": "NCT00062621",
      "title": "Combined Bone Marrow and Kidney Transplant for Multiple Myeloma With Kidney Failure",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Kidney Failure, Chronic",
        "Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "Combined bone marrow and kidney transplant",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 5,
      "start_date": "2003-06",
      "completion_date": "2006-12",
      "has_results": false,
      "last_update_posted_date": "2013-02-05",
      "last_synced_at": "2026-11-17T17:42:14.874Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00062621"
    },
    {
      "nct_id": "NCT01261247",
      "title": "Panobinostat in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Adult Nasal Type Extranodal NK/T-cell Lymphoma",
        "Anaplastic Large Cell Lymphoma",
        "Angioimmunoblastic T-cell Lymphoma",
        "Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue",
        "Hepatosplenic T-cell Lymphoma",
        "Nodal Marginal Zone B-cell Lymphoma",
        "Peripheral T-cell Lymphoma",
        "Post-transplant Lymphoproliferative Disorder",
        "Recurrent Adult Burkitt Lymphoma",
        "Recurrent Adult Diffuse Large Cell Lymphoma",
        "Recurrent Adult Lymphoblastic Lymphoma",
        "Recurrent Adult T-cell Leukemia/Lymphoma",
        "Recurrent Grade 1 Follicular Lymphoma",
        "Recurrent Grade 2 Follicular Lymphoma",
        "Recurrent Grade 3 Follicular Lymphoma",
        "Recurrent Mantle Cell Lymphoma",
        "Recurrent Mycosis Fungoides/Sezary Syndrome",
        "Recurrent Small Lymphocytic Lymphoma",
        "Small Intestine Lymphoma",
        "Splenic Marginal Zone Lymphoma",
        "Waldenstrom Macroglobulinemia"
      ],
      "interventions": [
        {
          "name": "panobinostat",
          "type": "DRUG"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        },
        {
          "name": "western blotting",
          "type": "GENETIC"
        },
        {
          "name": "DNA analysis",
          "type": "GENETIC"
        },
        {
          "name": "flow cytometry",
          "type": "OTHER"
        },
        {
          "name": "pharmacological study",
          "type": "OTHER"
        },
        {
          "name": "immunohistochemistry staining method",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER",
        "GENETIC"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 41,
      "start_date": "2011-01-17",
      "completion_date": "2019-12-02",
      "has_results": true,
      "last_update_posted_date": "2022-05-24",
      "last_synced_at": "2026-11-17T17:42:14.874Z",
      "location_count": 2,
      "location_summary": "Scottsdale, Arizona • Rochester, Minnesota",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01261247"
    },
    {
      "nct_id": "NCT06665555",
      "title": "Plasma and Intrapulmonary Pharmacokinetics of Ceftibuten and Ledaborbactam in Healthy Adults (18-55 Years)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Pharmacokinetics",
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "ledaborbactam etzadroxil",
          "type": "DRUG"
        },
        {
          "name": "ceftibuten",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Basilea Pharmaceutica",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 34,
      "start_date": "2024-11-04",
      "completion_date": "2025-03-17",
      "has_results": true,
      "last_update_posted_date": "2026-08-24",
      "last_synced_at": "2026-11-17T17:42:14.874Z",
      "location_count": 1,
      "location_summary": "Phoenix, Arizona",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06665555"
    }
  ]
}